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effects, angiogenesis, mitogenesis, and polypeptide hor-
mone secretion in multiple cell types (1, 2). Both EETs and 
HETEs are synthesized by cytochrome P450 (CYP450) mo-
nooxygenases, but their presence in cells does not entirely 
depend on acute de novo synthesis. Although initially be-
lieved to be transiently acting short-lived metabolites, both 
EETs and HETEs can replace acyl groups in membrane 
phospholipids; thus, the cellular content of these eicos-
anoids may also be influenced by reciprocal esterification 
and phospholipase pathways that have not been well-
characterized (3–6). We reported that long-chain acyl-CoA 
synthetase (ACSL) isoform 4 (ACSL4) can use EETs as a 
substrate (7), but because EET- and HETE-containing 
phospholipids are present in tissues that express low levels 
of ACSL4 (8, 9), we wondered whether one or more of the 
other ACSL isoforms might also activate these molecules to 
form EET- or HETE-CoAs that could be esterified to spe-
cific phospholipids.
Five ASCLs (ACSL1, -3, -4, -5, and -6) (EC 6.2.1.3) con-
vert FAs of 12–20 carbons to their corresponding FA-CoAs. 
Each ACSL isoform has been functionally differentiated by 
its FA chain length preference, tissue distribution, and sub-
cellular location, attributes that alter the ability of an indi-
vidual ACSL to channel FAs toward disparate metabolic 
fates (10).
Once activated, acyl-CoAs have multiple metabolic fates, 
including the synthesis of triacylglycerol, cholesterol esters, 
retinal esters, and phospholipids, -oxidation, FA elonga-
tion and desaturation, protein acylation, and use as signal-
ing molecules (10). Members of the ACS family require 
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Co-A and substrates with a carboxylic acid group in order 
to catalyze the thioesterification reaction. The thioesterifi-
cation two-step reaction is energetically costly, using the 
equivalent of two high-energy bonds (11, 12). This high 
energetic cost emphasizes the importance of the ACS-
catalyzed reaction as a regulatory node for the metabo-
lism of FAs.
The five ACSL isoforms were identified, cloned, and 
characterized by Yamamoto and his colleagues (8, 13–15), 
and most of our knowledge regarding their substrate pref-
erences comes from these initial studies. However, the sub-
strate preferences reported in these studies cannot be 
directly compared with each other because the enzymes 
were expressed differently and the methods used for activ-
ity assays varied. For activity studies of ACSL1, ACSL4, 
ACSL5, and ACSL6 [initially known as ACSL2 (16)], the 
enzymes were expressed in and purified from Escherichia 
coli, whereas ACSL3 was expressed and studied in COS7 
(monkey kidney) cells, but in each instance, the substrate 
concentration ranges and the specific Vmax and Km values 
were unclear (8, 13–15). Although substrate specificities 
for the ACSL isoforms were reported, direct and systematic 
comparisons of substrate preferences for each ACSL iso-
form were not performed.
The importance of substrate preference for a specific 
ACSL isoform suggests how and where a specific substrate 
will be metabolized. We report here the ACS enzyme kinet-
ics with different FA and eicosanoid substrates of the rat 
ACSL isoforms overexpressed in bacterial and mammalian 
cells. Further, we provide validation of the indirect spectro-
photometric ACS activity assay by showing LC-MS/MS evi-
dence that the product of the reaction produces an acyl 
thioester.
MATERIALS AND METHODS
Materials
AA, (±)-8,9-EET, (±)-11,12-EET, and (±)-14,15-EET were pur-
chased from Cayman Chemical (Ann Arbor, MI). Arachidonoyl-
CoA (20:4-CoA) was purchased from Avanti Polar Lipids 
(Alabaster, AL). All other FAs and reagents were purchased from 
Sigma (St. Louis, MO).
Construction of recombinant pFLAG-ACSLs and 
mammalian ACSL plasmid
cDNA was synthesized from either rat liver or brain total RNA 
(extracted using TRIzol; Invitrogen) and used as a template to 
amplify the ACSL open reading frames (high capacity cDNA re-
verse transcription kit; Applied Biosystems, Foster City, CA). Prim-
ers for amplification of ACSL1, ACSL3, ACSL4, ACSL5, and 
ACSL6 were designed to include the entire open reading frames, 
based on nucleotide sequences obtained from the GenBank data-
base (supplemental Table S1). ACSL amplification was performed 
by PCR with the designed primers. The amplified ACSL PCR 
products were ligated into either pFLAG-CTC vector (Sigma) or 
pcDNA3.1 vector (Invitrogen) digested with the same restriction 
enzymes. The sequences of pFLAG-ACSL and pcDNA3.1-ACSL 
fusion constructs were verified by the University of North Caro-
lina Automated Sequencing Facility.
Expression of recombinant F-ACSL proteins in E. coli
Recombinant F-ACSLs were expressed in E. coli DH5 after in-
duction with 1 mM IPTG at an A600 of 1.0. DH5 was grown in 
Terrific Broth (Life Technologies, Inc.) supplemented with ampi-
cillin (60 g/ml) at 30°C and shaken at 250 rpm. After a 12 h 
induction, cells were harvested by centrifuging at 4,800 g for 
10 min in a Sorvall HS-4 rotor. The cell pellet was resuspended in 
10 ml of 10 mM Tris (pH 7.4), 0.5 mM EDTA (TE) buffer. Resus-
pended cells were incubated with 100 g/ml lysozyme for 30 min 
on ice and then sonicated with six 10 s bursts, each followed by a 
10 s rest on ice. Cellular debris was removed from the cell lysates 
by centrifugation at 3,000 g for 10 min. Part of the supernatant 
was saved (cell extract), and the remainder was layered over a 2 ml 
cushion of 55% (w/w) sucrose topped with 0.5 ml of 5% (w/w) 
sucrose in TE buffer. After centrifuging in a Beckman SW41 rotor 
at 210,000 g for 3 h, the supernatant was removed (soluble frac-
tion). The membrane band at the interface was collected with a 
19 gauge needle and syringe. Protein concentrations were deter-
mined by the BCA method (Pierce).
Purification of the recombinant F-ACSL proteins
F-ACSLs were purified by Flag M2 column chromatography. 
The Flag M2 antibody affinity matrix (1 ml) (Sigma) was activated 
with 0.1 M glycine (pH 3.5), 50 mM Tris (pH 7.4), and 150 mM 
NaCl (TBS) buffer. DH5 membrane fractions containing over-
expressed F-ACSLs were solubilized in TBS containing 1% Triton 
X-100 and passed over the column four times. The column was 
washed three times with 12 ml of TBS (pH 7.4), and then eluted 
with five 1 ml aliquots of 100 g/ml Flag peptide (Sigma) dissolved 
in TBS buffer (pH 7.4).
Transient transfection of pcDNA3.1-ACSL1 and ACSL4
COS7 cells were routinely cultured in Dulbecco’s Modified 
Eagle’s Medium containing 10% fetal bovine serum. COS7 cells 
were plated at a cell density of 2.0 × 106 in 10 cm dishes and trans-
fected for 18 h after plating with 10 g of plasmid carrying rat 
ACSL1 or ACSL4 (XtremeGene HP; Roche). Cell homogenates 
were collected 48 h posttransfection in ice-cold medium A [10 mM 
Tris (pH 7.4), 250 mM sucrose, 1 mM EDTA, 1 mM dithiothreitol, 
and protease inhibitor mixture (Sigma)]. Homogenates were 
then centrifuged at 1,000 g for 10 min at 4°C. Total membranes 
were prepared by subjecting the supernatant to ultracentrifuga-
tion at 100,000 g for 1 h at 4°C. The resulting supernatant was 
removed and the membrane pellet was resuspended in ice-cold 
medium A. Aliquots were stored at 80°C until use.
Spectrophotometric ACS activity assay
Acyl-CoA synthetase (ACS) activity was assayed by coupling the 
reaction of ACS with those of adenylate kinase, pyruvate kinase, 
and lactate dehydrogenase and following the oxidation of NADH 
at 334 nm with a recording spectrophotometer (Beckman DU640) 
(17). The reaction mixture contained 100 mM Tris-HCl buffer 
(pH 8.0), 10 mM ATP, 15 mM MgCl2, 5 mM dithiothreitol, 150 mM 
KCl, 1.0 mM potassium phosphoenolpyruvate, 0.3 mM NADH in 
100 mM triethanolamine (pH 8.2), and either FA or eicosanoid 
(solubilized in 15 mM Triton X-100 and 0.1 mM EDTA). Then 
45 g adenylate kinase, 30 g pyruvate kinase, and 30 g lactate 
dehydrogenase were added in a total reaction volume of 1 ml. 
Varying amounts of either purified ACSL or COS7 cell mem-
branes were used to create a protein dependence curve such that 
1 g protein yielded ACS activity in a linear range. The reaction 
mixture was incubated for 1 min at 37°C, and the reaction was 
initiated by the addition of CoA (final concentration 600 M). 
Change in absorbance at 334 nm was measured every 10 s for 
5 min. The reaction rate was calculated using the slope and 
886 Journal of Lipid Research Volume 58, 2017
intercept created from an NADH standard curve with concentra-
tions from 0 to 0.2256 M.
Identification of AA-CoA and EET-CoAs by LC-MS/MS
Methods were adapted from Magnes et al. (18). Solid phase 
extraction was performed on Hypersep Retain PEP 60 mg, 3 ml 
cartridges (Thermo Fisher Scientific). Elution solvent was pre-
pared by mixing 50 ml water with 50 ml acetonitrile plus 100 l 
28% NH4OH solution and 5 l formic acid. Cartridges were con-
ditioned with 3 ml acetonitrile and then 3 ml water. Two hundred 
fifty microliters of reaction mixture were diluted with 2 ml water 
and loaded onto the cartridge. The cartridge was rinsed with 6 ml 
water before eluting acyl-CoAs in 2.5 ml of elution solvent.
Analysis was performed on an Ultimate 3000 UHPLC and 
Quantiva tandem mass spectrometer (Thermo Fisher Scientific.) 
The chromatography column was an Xselect CSH C18, 2.1 × 50 mm, 
3.5 m particles (Waters). Mobile phase A consisted of 1 ml 28% 
NH4OH solution, 50 l formic acid, and 1,000 ml water. Mobile 
phase B was acetonitrile. The starting mobile phase was 20% B and 
was held for 0.5 min before ramping to 40% B over 3.5 min. The 
column was held at 40% B for 2 min and then returned to 20% B 
for 3 min for re-equilibration. The injection volume was 4 l.
Samples were introduced to the mass spectrometer via an ESI 
source. The vaporizer temperature was 300°C and the ion transfer 
tube temperature was 325°C. Sheath, auxiliary, and sweep gas 
were set to 35, 20, and 1 arbitrary units, respectively. Spray voltage 
was 4,250 V for positive ion experiments and 3,750 V for nega-
tive ion experiments. Acyl-CoAs were detected via positive ion 
neutral loss scanning from m/z 900 to 1,400 with neutral loss set to 
507.1. The collision energy was set to 34 V and collision cell pres-
sure was 2 mTorr. Positive product ion spectra of acyl-CoAs were 
also obtained.
Western blot
FLAG column purified E. coli F-ACSLs (F-ACSLs) (6 g) and 
membranes from COS7 cells (50 g) were separated by electro-
phoresis on a 10% polyacrylamide gel and transferred to nitrocel-
lulose membranes (Bio-Rad). Protein expression of F-ACSLs was 
detected by anti-FLAG monoclonal antibody (Sigma; F1804). For 
ACSL1 and ACSL4 expressed in mammalian cells, rabbit anti- 
human ACSL1 (Cell Signaling, Danvers, MA; 4047) and rabbit anti-
human ACSL4 (19), a generous gift from S. M. Prescott (University 
of Utah, Salt Lake City, UT), were used to detect ACSL1 and 
ACSL4, respectively. GAPDH was used as the loading control (Ab-
cam, Cambridge, MA; ab8245). To determine the purity of FLAG-
column purified F-ACSLs, both E. coli lysates (40 g) and purified 
F-ACSLs (6 g) were separated by electrophoresis on a 10% poly-
acrylamide gel and stained with Coomassie brilliant blue.
Data analyses
Data are expressed as mean ± SEM from three separate experi-
ments. Michaelis-Menten kinetic enzyme activity curves were 
drawn and Vmax and Km values derived using GraphPad Prism® 6.0 h 
(San Diego, CA).
RESULTS
Bacterial and mammalian overexpressed ACSL isoforms 
are able to activate EETs and HETEs
EETs and HETEs are oxidative products of CYP450 ep-
oxygenases, using AA as the substrate. EETs and HETEs 
function as autocrine and paracrine signals that regulate 
vasodilation, ion channel activation, anti-inflammatory 
Fig. 1. FLAG column purified F-ACSL isoforms overexpressed in 
E. coli were resolved by PAGE and immunoblotted with anti-FLAG 
antibody.
effects, angiogenesis, mitogenesis, and polypeptide hor-
mone secretion (2). They are incorporated into phospho-
lipids by a CoA-dependent process that plays a significant 
role in regulating EET actions on either a membrane re-
ceptor or as a direct interactor with intracellular effectors 
(2). We previously reported that purified bacterial F-ACSL4 
can use (±)-8,9-EET, -11,12-EET, and -14,15-EET as sub-
strates in an indirect ACS activity assay (7). Because AA is 
the precursor for all eicosanoids and because eicosanoids 
contain a terminal carboxyl group, we hypothesized that 
the ACSL isoforms would differ in their activation of eico-
sanoid substrates. Using the sequences of rat ACSL iso-
forms (supplemental Table S1), we constructed bacterial 
plasmids containing the cDNA for each isoform linked to a 
C terminus FLAG tag (pACSL-FLAG). Bacterial pACSL-
FLAG plasmids were transfected and induced in E. coli and 
the resulting recombinant proteins were purified by col-
umn chromatography. To ensure expression of the recom-
binant proteins, we resolved 6 g of FLAG column purified 
F-ACSLs by PAGE, blotted, and probed with anti-FLAG an-
tibody (Fig. 1). Because there were doublet bands observed 
in the immunoblot, we wanted to ensure the purity of the 
FLAG-column purified recombinant F-ACSLs and again re-
solved each purified F-ACSL isoform (6 g) and the E. coli 
lysates (40 g) by PAGE and stained with Coomassie bril-
liant blue (supplemental Figs. S1, S2). Each purified 
F-ACSL showed a double band with the upper band (80–75 
kDa) being the predicted molecular mass for each F-ACSL 
isoform. We suspect that the lower bands (60 kDa) are 
degradation products. Using purified bacterial expressed 
F-ACSL enzymes, we performed indirect ACS activity assays 
using 1 g protein with a fixed (5 M) final concentration 
of EETs and HETEs as substrates. To validate our indirect 
ACS activity assay and ensure that eicosanoid-CoAs were 
produced, we performed the indirect ACS activity assay 
with F-ACSL4 using 5 M AA, 8,9-EET, 11,12-EET, and 
14,15-EET as substrates. Upon reaction termination, the 
reaction products were subjected to LC-MS/MS analy-
ses. Comparing the authentic reference standard, arachi-
donoyl-CoA (20:4-CoA) (Fig. 2B), to the reaction product 
of F-ACSL4 and AA (Fig. 2C), we found a distinct peak at 
m/z 1,054 corresponding to arachidonoyl-CoA [M+H]+. 
During positive ion ESI-MS/MS, a distinctive neutral loss of 
507.1 Da corresponds to the loss of the phosphoadenosine 
diphosphate (CoA moiety) that is common to all acyl-CoAs 
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(supplemental Fig. S3) (18). We next analyzed the reaction 
products of F-ACSL4 and the EETs, with the expected m/z 
of the EET-CoAs to be 1,070 (AA → 1,054 plus oxygen → 
16). Indeed, for each of the EETs tested, we observed 
strong peaks at m/z 1,070 corresponding to EET-CoAs 
(Fig. 2D–F). Further, positive product ion scans of reaction 
products showed ion peaks that were consistent with the 
formation of EET-CoAs (supplemental Fig. S4). Taken 
Fig. 2. Neutral loss of phosphoadenosine diphosphate (507.1 Da) scan of the [M+H]+ ions from F-ACSL4 no FA blank control (A), authen-
tic AA-CoA positive control (Avanti Polar Lipids) (B), reaction product from F-ACSL4 and AA (C), reaction product from F-ACLS4 and 
8,9-EET (D), reaction product from F-ACSL4 and 11,12-EET (E), and reaction product from F-ACSL4 and 14,15-EET (F). AA-CoA 1,054.3 
Da and EET-CoAs 1,070.4 Da.
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together, the LC-MS/MS analyses of the indirect ACS activ-
ity assay reaction products provide strong evidence that 
EET-CoA products are formed.
Following validation that the indirect ACS activity assay 
produced EET-CoA products, we assayed each of the 
F-ACSL isoforms with EETs and HETEs as substrates. Each 
of the F-ACSL isoforms was able to convert both substrates to 
acyl-CoA products, but we observed differences in substrate 
preference among the isoforms (Fig. 3). For example, 
F-ACSL4 exhibited the greatest activity with EETs, whereas 
F-ACSL1 showed the greatest activity with HETEs (Fig. 3A, 
B). Interestingly, compared with the parent molecule, AA, 
F-ACSL1 had greater activity with all three HETE species 
tested (Fig. 3B). ACS activity with F-empty vector using the 
substrates tested was not observed (data not shown).
Previous reports describing the substrate preferences of 
ACSL isoforms were based on proteins expressed and puri-
fied from recombinant bacteria (8, 14, 15). Because ACSLs 
are normally membrane bound proteins, we wondered 
whether there were differences between purified ACSL iso-
forms expressed in bacteria versus the ACSL isoforms over-
expressed in membranes of mammalian cells. To answer 
this question, we cloned rat ACSL1 and ACSL4 into the 
mammalian pcDNA3.1 expression vector and transformed 
COS7 cells to overexpress ACSL1 and ACSL4 isoforms 
(supplemental Table S1). We selected ACSL1 and ACSL4 
because they had the greatest ACS activity from the bacte-
rial expressed F-ACSLs using the eicosanoids as substrates. 
To ensure overexpression, we resolved 50 g of mem-
branes by PAGE, blotted and probed with anti-ACSL1 or 
anti-ACSL4 antibody (Fig. 4). Both ACSL1 and ACSL4 
were overexpressed compared with control COS7 cells 
transfected with the empty vector. Interestingly, in COS7 
cells, the basal expression of ACSL4 appeared higher than 
the overexpressed ACSL1. Despite the high amount of 
basal ACSL4 protein expression, the indirect ACS activity 
using palmitate was 1,000-fold lower compared with what 
we observed with the overexpressed ACSL isoform indirect 
ACS activities (nanomoles per minute per milligram 
protein vs. micromoles per minute per milligram protein, 
respectively) (supplemental Fig. S7). We performed indi-
rect ACS activity assays using 1 g protein from total mem-
brane preparations using the same fixed (5 M) final 
concentration of EETs and HETEs as substrates. To vali-
date that EET-CoAs were produced with COS7 overex-
pressed ACSL4, we again performed indirect ACS activity 
assays and subjected the reaction products to LC-MS/MS 
analyses. As with the F-ACSL4 reaction products, the COS7-
ACSL4 reactions with 5 M AA, 8,9-EET, 11,12-EET, and 
14,15-EET as substrates produced AA-CoA and EET-CoA 
products, respectively (Fig. 5). Further, chromatographic 
retention times of the COS7-ACSL4 reaction products for 
AA and EETs corresponded to those from the F-ACSL4 re-
action products (supplemental Figs. S5, S6). However, the 
m/z 1,054 and 1,070 peaks were much less intense com-
pared with the F-ACSL4 reaction products, probably 
because the F-ACSLs were purified enzymes, unlike the 
Fig. 3. Purified F-ACSLs can activate either EETs (A) 
or HETEs (B) as substrates. ACS activity with different 
substrates at 5 M (final concentration). Error bars 
reflect SEM from three separate experiments. S.A., 
specific activity.
Fig. 4. Overexpressed ACSL1 and ACSL4 in COS7 cells. Immu-
noblots of membranes (50 g) from COS7 cells overexpressing 
ACSL1 (A) and ACSL4 (B). GAPDH served as loading control. EV, 
empty vector.
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COS7-ACSLs, which were membrane bound and surrounded 
by lipids, proteins, and cofactors. It is likely that these mem-
brane constituents impact the activity of the ACSL. Despite 
these less intense peaks, overexpressed COS7-ACSL4 was 
able to synthesize EET-CoAs.
Comparing the ACS activities between COS7-ACSL1 and 
COS7-ACSL4 with EET and HETE as substrates, we found 
that ACSL4 had greater activity with both EETs and HETEs 
compared with ACSL1 (Fig. 6). Further, the mammalian 
expressed ACSL1 and ACSL4 had greater activity with the 
Fig. 5. Neutral loss of phosphoadenosine diphosphate (507.1 Da) scan of the [M+H]+ ions from COS7-ACSL4 and no FA control (A), reac-
tion product from COS7-ACSL4 and AA (B), reaction product from COS7-ACSL4 and 8,9-EET (C), reaction product from COS7-ACSL4 and 
11,12-EET (D), and reaction product from COS7-ACSL4 and 14,15-EET (E). AA-CoA 1,054.3 Da and EET-CoAs 1,070.4 Da.
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parent AA than with EETs or HETEs, which was not seen 
with the bacterial F-ACSL1 and F-ACSL4 assays. Again, 
these differences in ACS activity are likely due to the mem-
brane constituents retained in mammalian preparations, 
but not in the purified F-ACSLs.
FA substrate preferences of ACSL isoforms expressed in 
mammalian cells differ from those expressed in bacteria
Because of previous reports describing the substrate 
preferences of ACSL isoforms from purified recombinant 
bacteria and because we identified substrate preference 
differences using EETs and HETEs between bacterial 
and mammalian expressed ACSL isoforms, we wondered 
whether there were differences in substrate preference for 
FAs based on whether the ACSL isoform was expressed in 
bacteria or expressed in mammalian membranes. Using 
FAs of differing chain length and degree of unsaturation 
(palmitate, 16:0; oleate, 18:1; stearate, 18:0; linoleate, 
18:2; AA, 20:4) at concentrations ranging from 2.5 M to 
100 M, we performed indirect ACS activity assays (17) 
using the purified F-ACSL isoforms to characterize the 
enzyme kinetics. The plotted Michaelis-Menten kinetic 
Fig. 6. ACSL1 and ACSL4 overexpressed in COS7 
cells use both EETs and HETEs as substrates. ACS ac-
tivity with 5 M final substrate concentrations of AA, 
8,9-EET, 11,12-EET, 14,15-EET, 5-HETE, 12-HETE, and 
15-HETE. Error bars reflect SEM from three separate 
experiments. S.A., specific activity.
Fig. 7. Michaelis-Menten kinetic enzyme activity 
curves from purified F-ACSL isoforms assayed spec-
trophotometrically with different FAs. F-ACSL1 (A), 
F-ACSL3 (B), F-ACSL4 (C), F-ACSL5 (D), and F-ACSL6 
(E). Data points represent the mean of determina-
tions from proteins obtained in three independent 
experiments.
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enzyme activity curves (Fig. 7) showed that each F-ACSL 
isoform had activity with each substrate, but that substrate 
preferences were distinct. For F-ACSL1, -3, -5, and -6, the 
apparent Vmax values were highest with palmitate (Table 1); 
however, similar to a previous report (8), the Vmax and Km 
values of F-ACSL4 were greatest with AA [7,180 ± 229 
mol/min/mg and 11.4 ± 1.3 M, respectively (Table 1)]. 
The apparent Vmax and Km values obtained from recombi-
nant proteins show different orders of FA substrate prefer-
ences in Table 1 and Table 2.
Because we noted differences in substrate preference be-
tween loss-of-function rodent models of ACSL1 (20) and 
the purified bacterial expressed ACSLs, we suspected that 
substrate preference would differ in the mammalian ex-
pressed ACSL isoforms. Indeed, similar to the overex-
pressed purified F-ACSL isoforms in bacteria, the substrate 
preferences, based on the apparent Vmax and Km values, dif-
fered between COS7 cell overexpressed ACSL1 and ACSL4 
isoforms (Fig. 8, Tables 3, 4).
Activities with 16:0 were highest for both purified re-
combinant F-ACSL1 and the COS7 cell overexpressed 
ACSL1, but marked differences were observed for sub-
strates with chain lengths longer than 16 carbons and 
for unsaturated FAs. For example, recombinant F-ACSL1 
preferred 20:4, whereas COS7-ACSL1 did not (Tables 1, 3). 
Major differences in substrate preference were not 
observed between recombinant F-ACSL4 and COS7-
ACSL4, but we confirmed the previous findings that 
ACSL prefers 20:4 (8), a preference that was not af-
fected by ACSL4 expression in bacteria compared with 
expression in mammalian cells. Taken together, these 
data suggest that ACSL activity and substrate preference 
depend on multiple factors, including the substrate, mem-
brane character, coactivators, inhibitors, interactions with 
other enzymes, ACSL cellular location, and ACSL tissue 
expression.
DISCUSSION
AA is converted to potent eicosanoid signaling mole-
cules by the cyclooxygenase, lipoxygenase, and CYP450 
monooxygenase pathways, which produce both EETs and 
HETEs by CYP epoxygenases and CYP -oxidases, respec-
tively (21). EETs and HETEs have multiple biologic func-
tions that have been primarily defined in vascular and 
renal systems, including vasodilation, ion channel activa-
tion, anti-inflammatory effects, angiogenesis, mitogenesis, 
regulation of coagulation, and polypeptide hormone se-
cretion. Despite the focus on the free eicosanoids, most 
EETs and HETEs are in cell membranes, esterified in glyc-
erophospholipids (4, 5, 22). The mechanism by which 
EETs and HETEs exert their biological effects is not en-
tirely known, but the presence of esterified EETs and 
HETEs in phospholipids suggests that they might either 
alter membrane dynamics that change receptor or channel 
activity or serve as a preformed reservoir that can be re-
leased by activated phospholipases potentially leading to 
downstream receptor activation (1, 2, 23). Further, the es-
terification of EETs and HETEs into glycerophospholipids 
could serve as a means to “de-activate” these signaling mol-
ecules. The incorporation of EETs and HETEs into phos-
pholipids requires a CoA-dependent process (5, 24). Once 
the EET or HETE is activated by an ACS, it can be esterified 
by a phospholipid acyltransferase, such as membrane-
bound O-acyltransferase (MBOAT)5 (MBOAT5/LPCAT3) 
or MBOAT7 (MBOAT7/LPIAT1) (Fig. 9) (25). Indeed, we 
show here that each of the ACSL isoforms is able to activate 
TABLE 1. Vmax values from purified F-ACSLs with various substrates
Vmax (mol/min/mg)
16:0 18:0 18:1 18:2 20:4
F-ACSL1 3,754 ± 100a 2,874 ± 74 2,089 ± 108 1,635 ± 33 3,363 ± 104
F-ACSL3 2,763 ± 98a 2,099 ± 33 2,109 ± 52 1,394 ± 31 2,627 ± 44
F-ACSL4 4451 ± 60 2,737 ± 45 2,366 ± 79 1,231 ± 44 7,180 ± 229a
F-ACSL5 5,053 ± 209a 2,164 ± 39 3,726 ± 44 1,351 ± 35 1,880 ± 49
F-ACLS6 3,993 ± 105a 1,725 ± 31 2,238 ± 35 1,763 ± 55 1,682 ± 69
Vmax values derived from kinetics data from Fig. 7 where data points are the mean of determinations from 
proteins obtained in three independent experiments.
a Indicates the substrate with which the greatest ACS activity is achieved for each F-ACSL.
TABLE 2. Km values from purified F-ACSLs with various substrates
Km (M)
16:0 18:0 18:1 18:2 20:4
F-ACSL1 2.7 ± 0.4 6.6 ± 0.7 6.7 ± 1.4 5.0 ± 0.4 6.3 ± 0.8
F-ACSL3 4.0 ± 0.7 3.1 ± 0.2 5.3 ± 0.6 7.3 ± 0.6 4.3 ± 0.3
F-ACSL4 4.5 ± 0.3 2.9 ± 0.2 16.7 ± 1.9 4.0 ± 0.6 11.4 ± 1.3
F-ACSL5 6.5 ± 1.1 4.4 ± 0.4 6.3 ± 0.3 5.8 ± 0.6 1.8 ± 0.3
F-ACLS6 3.0 ± 0.4 4.4 ± 0.4 4.4 ± 0.3 6.0 ± 0.8 2.9 ± 0.6
Km values derived from kinetics data from Fig. 7 where data points are the mean of determinations from proteins 
obtained in three independent experiments.
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EETs and HETEs to produce EET-CoAs and HETE-CoAs, 
respectively.
The CYP450 monooxygenases that produce EETs and 
HETEs are expressed in the heart, vasculature, kidney, 
brain, liver, lung, spleen, blood cells, testis, and pancreas 
(26). Because the different ACSL isoforms differ in their 
EET and HETE substrate specificities, the expression of 
specific ACSL isoforms (27) may directly influence EET 
and HETE metabolism and action in a tissue-specific man-
ner and suggest why these eicosanoids might differ in their 
biological functions and metabolism.
ACSs catalyze the thioesterification of FAs with CoA to 
yield fatty acyl-CoAs. After activation, the fatty acyl-CoA 
products have multiple metabolic fates, including mem-
brane synthesis, energy production, storage, and the pro-
duction of signaling molecules. Despite the fact that 
each ACSL isoform performs the identical reaction, the 
isoforms differ in their tissue and subcellular distribution 
and likely substrate preference. We show here that FA 
preferences of the ACSL isoforms are similar, but not 
identical, when determined with purified E. coli prepara-
tions versus COS7 cell membranes. The reason for the dif-
ferences in substrate preference between the purified 
bacterial and membrane bound mammalian expressed 
ACSL isoforms is multifactorial, including membrane 
character, coactivators, inhibitors, interactions with other 
enzymes, specific ACSL cellular location, specific ACSL 
expression, and posttranslational modification (6). In-
deed, we have previously shown that ACSL1 is differen-
tially phosphorylated and acetylated in different cell 
types (28). Furthermore, in cardiac muscle, where the 
ACSL1 isoform predominates, ACSL activity is 3.5 times 
greater with 18:2 than with 16:0, 18:0, 18:1, or 20:4 (20), 
strongly suggesting that tissue-specific composition of 
membranes may also influence ACSL substrate prefer-
ence. Collectively, the substrate preferences presented 
here and those from previous animal model experiments 
indicate that when describing ACSL substrate prefer-
ence, it must be placed into the context of the model 
system.
Our results with recombinant expressed ACSL isoforms 
are comparable to substrate preferences that were previ-
ously reported (8, 14, 15) in that ACSL1, -5, and -6 pre-
ferred 16:0, whereas ACSL4 preferred 20:4. Because the 
ACS activity of ACSL3 was originally reported from ex-
pression in COS7 cells, we were not able to directly com-
pare our substrate preference from bacterial recombinant 
F-ACSL3. However, our results that F-ACSL3 prefers 16:0 
agree with the preferences reported for ACSL3 ex-
pressed in COS7 cells (13). We also observed higher ACS 
specific activities from recombinant expressed ACSL 
isoforms than previously reported. While there are multiple 
Fig. 8. Michaelis-Menten enzyme activity curves 
from membranes of COS7 cells overexpressing ACSL1 
(A) or ACSL4 (B) with different FAs. Data points rep-
resent the mean of determinations from three inde-
pendent experiments.
TABLE 3. Vmax values from overexpressed ACSL1 and ACSL4 COS7 membranes with various substrates
Vmax (mol/min/mg)
16:0 18:0 18:1 18:2 20:4
COS7-ACSL1 3,068 ± 54a 2,342 ± 74 2,607 ± 63 2,525 ± 75 1,745 ± 48
COS7-ACSL4 1,990 ± 69 1,240 ± 29 466 ± 11 1,011 ± 30 4,339 ± 102a
Vmax values derived from kinetics data from Fig. 8 where data points are the mean of determinations from 
proteins obtained in three independent experiments.
a Indicates the substrate with which the greatest ACS activity is achieved for each COS7 ACSL.
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explanations for these differences, the most likely relate 
to how we made the ACSL isoform constructs, which con-
tained a FLAG epitope, and our method of purification. 
We likely obtained purer enzyme preparations because 
we used FLAG affinity column purification. It seems less 
likely that the fusion of FLAG to the C terminus enhances 
ACSL activity.
Our measures of ACS-specific activity between the dif-
ferent ACSL isoforms and substrates have several limita-
tions. First, three different methods have been used 
historically to measure ACS activity; these include direct 
HPLC measurements (29) or 3H-labeled CoA (30), and 
the indirect coupled assay measuring the reduction of 
NADH (17). Each method has its own specific pitfalls, 
but in all cases the methods measure only relative activi-
ties for a given experimental condition. As a result, it is 
not possible to compare ACS activities obtained with dif-
fering methods. In this study, to allow comparisons of 
substrate preference, we used the same assay for recom-
binant and cell expressed ACSL isoforms, and we main-
tained the same experimental conditions. A second 
limitation concerns substrate concentration; the amount 
of substrate used in these assays far exceeds the intracel-
lular concentration of unbound free FA, calculated to be 
less than 1 M (31). Furthermore, we cannot know the 
FA concentration at the enzyme’s active site. These diffi-
culties make it difficult to relate in vitro to in vivo ACS 
activities. Until we have more sensitive methods to measure 
the in vivo fluxes of free FAs and acyl-CoAs simultaneously, 
we are forced to rely on the current measures of ACS 
activity. Finally, our in vitro ACS activity assays do not 
account for the mixtures of FAs that are normally pre-
sented to ACSLs. To define a true substrate preference, 
an ACSL must select a FA from a cellular pool of FAs and 
FA metabolites.
We have shown, using a validated indirect assay for ACS 
activity, that whereas each ACSL isoform catalyzes the 
same reaction, individual ACSL isoforms differ in sub-
strate preferences that appear to be modified depending 
on the model system in which the ACSL is expressed. 
These differences likely allow specificity in FA and FA me-
tabolite partitioning toward different metabolic fates in a 
cellular or tissue-dependent manner. We have also dem-
onstrated that each of the ACSL isoforms, whether ex-
pressed in bacterial or mammalian cells, can use both 
EETs and HETEs as substrates. Given the importance of 
these signaling eicosanoids and the ability of the ACSL 
isoforms to activate them, further efforts should be directed 
toward determining whether the functions of esterified 
eicosanoids differ from those that have been newly formed, 
as well as determining how ACSLs and acyltransferases 
work together to channel eicosanoids toward membrane 
storage pools.
The authors would like to thank Dr. Diana Stafforini for 
assistance with procuring the anti-ACSL4 antibody.
TABLE 4. Km values from overexpressed ACSL1 and ACSL4 COS7 membranes with various substrates
Km (M)
16:0 18:0 18:1 18:2 20:4
COS7-ACSL1 2.1 ± 0.2 11.5 ± 1.3 14.7 ± 1.2 7.0 ± 0.8 7.3 ± 0.8
COS7-ACSL4 24.8 ± 2.5 12.5 ± 1.0 3.6 ± 0.4 13.3 ± 1.4 7.5 ± 0.7
Km values derived from kinetics data from Fig. 8 where data points are the mean of determinations from proteins 
obtained in three independent experiments.
Fig. 9. Scheme of the synthesis of EETs from un-
esterified AA catalyzed by CYP450 monooxygenase 
(Cyp450 MOase). EETs can then be activated by ACSL 
to produce EET-CoA. Once activated, the EET-CoA 
can be esterified by a phospholipid acyltransferase 
such as MBOAT5/LPCAT3, specific to lysophosphati-
dylcholine and lysophosphatidylethanolamine, or 
MBOAT7/LPIAT1, specific to lysophosphatidylinosi-
tol, to produce oxidized phospholipids.
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